Federal Cannabis Rescheduling Update: Where the Process Stands March 2026

Executive Summary

The federal effort to reschedule cannabis remains in progress. While the U.S. Department of Health and Human Services (HHS) issued the original recommendation to move cannabis from Schedule I to Schedule III, the process entered an “expedited” phase in late 2025. Following a Presidential Executive Order in December 2025, the Drug Enforcement Administration (DEA) and the Department of Justice have been directed to finalize the reclassification in the most efficient manner permissible under federal law. For investors and operators, rescheduling represents a potentially historic shift, particularly regarding taxation and regulatory positioning, but while the momentum accelerated at the end of 2025, the final effective date remains pending. This update outlines the current status of the process, recent executive actions, and what stakeholders should monitor throughout 2026.

Federal cannabis rescheduling has moved from a slow-walked policy discussion to a priority administration deliverable. Following a year of intense evaluation, the conversation is no longer about if the DEA will act, but how quickly it can finalize the rule amidst ongoing procedural steps and potential litigation.

For investors, operators, and executives, 2026 is emerging as a “split-screen” year: cannabis is moving toward a less restrictive federal status, even as the broader hemp market faces potential contraction.

What Has Happened So Far

The current rescheduling process began when HHS completed its scientific evaluation and formally recommended a move to Schedule III.

Key milestones include:

• HHS Recommendation: The binding scientific finding that cannabis has an accepted medical use.
• December 2025 Executive Order: President Trump signed the “Increasing Medical Marijuana and Cannabidiol Research” order, directing the Attorney General to finalize Schedule III reclassification expeditiously.
• 2026 Spending Bill Resolution: In early 2026, the Senate removed restrictive language from the federal spending bill that would have blocked the use of funds for rescheduling, clearing a critical legislative hurdle.
• Medicare Integration: For the first time, federal agencies have begun detailing plans, tentatively set to launch in April 2026, to cover certain hemp-derived CBD products under Medicare programs, signaling a broader shift in federal medical acceptance.

While the Executive Order has increased the pressure for a result, the DEA maintains that it must still follow the administrative steps required by the Controlled Substances Act (CSA) to ensure the final rule is “litigation-ready.”

Where the Process Stands Now

The rescheduling decision is currently in the final rulemaking phase at the DEA.

This stage includes:

• Internal Review of Public Comments: Processing the tens of thousands of comments submitted following the original proposal.
• Administrative Hearing Procedures: Navigating the formal hearing track
• Final Rule Publication: The ultimate step where the DEA publishes the change in the Federal Register, establishing an official effective date.

While the administration is pushing for a conclusion in 2026, the legal requirement for a robust administrative record means a “surprise” immediate change is unlikely.

What Rescheduling Would and Would Not Change

If cannabis is moved to Schedule III, it would represent the most significant shift in federal drug policy in over 50 years, but it is not full legalization.

Potential implications could include:

• Removal of IRS Section 280E: Plant-touching businesses would no longer be barred from taking ordinary business deductions, dramatically improving effective tax rates.
• Recognition of Medical Use: Federal acknowledgment of the safety and efficacy of cannabis for specific medical conditions.
• Expanded Research and Access: A significant reduction in the bureaucratic barriers for clinical trials and potential federal insurance coverage for certain applications.

However, rescheduling would not:

• Legalize “Adult-Use” at the Federal Level: Recreational sales remain technically illegal under federal law outside of the FDA-approved drug framework.
• Provide Retroactive Tax Relief: Current guidance suggests 280E relief will likely be prospective (applying only to tax years after the rule is finalized), not a refund for past years.
• Solve Banking Obstacles: While it improves the climate, Schedule III status does not automatically grant the industry full access to the federal banking system.

Why the Timeline Remains Uncertain

Despite the executive mandate to move quickly, the “expeditious” path is still subject to the speed of the federal bureaucracy and the courts.

Several factors contribute to the 2026 uncertainty:

• Procedural Hurdles: The need to appoint new judicial oversight for administrative hearings after recent retirements.
• Litigation Exposure: Both pro- and anti-reform groups are expected to challenge the final rule, which could result in court-ordered stays.
• The “Hemp Compliance Cliff”: Federal agencies are simultaneously working on a contraction of the hemp market, with a ban on many intoxicating hemp-derived products expected in late 2026. This creates a complex, dual-track regulatory environment.

What This Means for Investors and Operators

For the industry, the current phase is best viewed as strategic positioning. Key considerations include:

• Tax Modeling: Businesses should be modeling their financials for a post-280E environment while remaining disciplined in their current tax compliance.
• Medicare and CBD Opportunities: The launch of the Medicare CBD pilot program in April 2026 offers a potential new frontier for operators with medical-grade product lines.
• Operational Discipline: Businesses structured for efficiency and state-level compliance are best positioned to leverage the shift if and when the “Final Rule” is published.

What to Watch Next

As we move through the second quarter of 2026, keep a close eye on:

• Issuance of the DEA’s Final Rule: The definitive signal that the reclassification is complete.
• Medicare Pilot Results: The early success or failure of the $500 CBD coverage initiative.
• Court Filings: Any requests for injunctions or stays that could pause the implementation of Schedule III.
• Hemp Policy Updates: Legislative or agency moves that tighten the “0.3% THC” standards for consumable hemp.

The Bottom Line

Federal cannabis rescheduling is closer than it has ever been, driven by a rare alignment of executive pressure and legislative clearing. However, for investors and operators, the opportunity lies in preparation, not assumption. Rescheduling will help to normalize the financial landscape, but disciplined strategy and operational strength will remain the primary drivers of long-term success in the evolving 2026 marketplace.

About Cannabis Business Advisors

For operators, investors, and entrepreneurs navigating cannabis policy and emerging markets, understanding how regulatory developments translate into operational strategy is critical.

Cannabis Business Advisors (CBA) tracks legislative developments, regulatory changes, and market dynamics across the United States to help industry leaders make informed decisions in a rapidly evolving industry. If you are evaluating opportunities in the cannabis market or want to discuss how regulatory shifts could impact market entry and compliance strategy, contact us at 602-290-9424 for additional insights.

This article is part of CBA’s ongoing state policy intelligence series tracking regulatory developments across emerging cannabis markets.

The Cannabis Business Advisors have more than thirty years of combined industry experience, spanning across the U.S. and around the globe. C.B. Advisors offers a comprehensive suite of services, including application and licensing preparation, operational analysis, merger and acquisition support, policy and procedures, exit strategy guidance, and business development planning. Stay up to date on the latest cannabis news with The CB Advisors!

Contact Info@thecannabisbusinessadvisors.com for more information on how to apply for a cannabis business license.